Quick Search  in all journalsin this journalin this issue Journals Home Drugs of Today Issues Drugs of Today Policies & Guidelines Permissions My Profile Contact Us Shopping Cart Purchase History

	Drugs of Today		Register or sign in
	Drugs Today 2020, 56(11): 705 ISSN 1699-3993 e-ISSN 1699-4019 Copyright 2020 Clarivate CCC: 1699-3993 DOI: 10.1358/dot.2020.56.11.3178111
	Crizanlizumab in vaso-occlusive crisis caused by sickle cell disease Gardner, R.V.
	Sickle cell disease (SCD) is a genetic disorder characterized by a single gene mutation leading to polymerization of erythrocytes, with subsequent assumption of a "sickle" shape. However, polymerization is just one aspect of the disorder's pathology. It is also characterized by abnormalities in nitric oxide utilization and vasculopathy; generation of reactive oxygen species; hemolysis; hypercoagulability; and altered rheology including abnormal leukocyte rolling along endothelium, and sickle cell-endothelial and cell-cell adhesion. The latter phenomenon is associated with increased P- and E-selectin expression and creation of a proadhesive endothelial environment. The anti-P-selectin humanized monoclonal antibody crizanlizumab functions through selective inhibition of P-selectin. At a dose of 5 mg/kg in a clinical trial, it led to a 45.3% decline in the median annual crisis rate in individuals with SCD. Tolerability was good and the adverse event profile was acceptable. In this review, results of the clinical trials involving this drug and specific side effects are outlined. Analysis of cost efficacy is touched on, with an examination of the economic and social burden of SCD. Full Text: PDF

	© Clarivate. All rights reserved.
	Copyright Notice	Terms of Use	Privacy Statement	Cookie Policy	Manage cookie preferences